OncoMatch/Clinical Trials/NCT06793241
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
Is NCT06793241 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells for b-cell acute lymphoblastic leukemia.
Treatment: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells — A Clinical Study on the Safety and Effectiveness of donor derived CD19 CAR-T Cells in the treatment of R/R B-cell acute lymphoblastic leukemia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — standard or remedial
No CR was obtained after standard chemotherapy; CR was induced for the first time, but the duration of CR was less than 12 months; R/R B-ALL that does not work after the first or more remedial treatments; Two or more relapses
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: allowed if ≥100 days since transplant
Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation
Cannot have received: anti-cancer chemotherapy or other drugs
Exception: allowed if >2 weeks prior to screening
Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening
Lab requirements
Blood counts
Absolute neutrophil count: ≥ 0.5×10^9/L; Platelet: ≥ 30×10^9/L; Hemoglobin ≧60g/L
Kidney function
creatinine ≤176.8 (μmol/L)
Liver function
Total bilirubin ≤51 (μmol/L), ALT/AST ≤ 3 times the upper limit of normal
Cardiac function
Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%
Total bilirubin ≤51 (μmol/L), ALT/AST ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L); Absolute neutrophil count: ≥ 0.5×10^9/L; Platelet: ≥ 30×10^9/L; Hemoglobin ≧60g/L; Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06793241 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation, anti-cancer chemotherapy or other drugs disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages